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A collection of 260 Candida strains isolates recovered from 198 patients from 13 different 
medical centers in Jabalpur over a period of 5 years.  These were tested for resistance to 
various antifungals according to the guidelines of NCCLS documents M 38-P by various 
methods. The isolates which were found to be resistant to synthetic antifungals were 
selected and subjected to antifungal testing against natural herbs and spices.Amongst all the 
spices and natural herbs tested garlic was found to the most effective against Candida 
strains. 
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Introduction 
Antimicrobial resistance surveillance serves many 
purposes. The most common of which is detection and tracking 
of resistance trends and emerging new threats11,13,14,16. 
Clinically this is important for treatment recommendations and 
as a means to assess the prevalent pathogens causing serious 
infections. The isolates collected in this program can be used 
to assess the activities of new antimicrobial agents and to aid 
in the development and validation of new susceptibility 
methods11,16,10. 
Over the past few decades the incidence of fungal 
infections has increased. The treatment of choice for infected 
patients remains amphotericin B, itraconazole, voriconazole 
etc. the appropriate susceptibility is decided by various in vitro 
susceptibility methods2,12,15,20,23,24. The studies to date that 
have documented the efficacies of agar based methods for the 
testing of susceptibilities to fluconazole or voriconazole have 
generally included adequate number of Candida albicans 
species but few Candida glabrata isolates. From susceptibility 
testing one can determine the resistivity of the clinical isolate to 
various antifungals by determining the MIC range against a 
sufficiently large number of isolates. 
Apart from the synthetic antifungal antibiotic the naturally 
occurring herbal products and spices are known to have 
powerful antifungal properties. Research has proved their 
antifungal activities. Herbs like goldenseal, myrrh, walnut, 
licorice, lemongrass and spices like turmeric, cinnamon, clove, 
ajwain and medicinal plants like neem, tulsi, eucalyptus etc. 
have a great antifungal profile. Even the combination of these 
works in synergy and gives better results then a single 
herb1,19,22. 
Materials and Methods  
Organism: A total of 260 clinical isolates of Candida species 
obtained from 13 medical centers of Jabalpur were tested .The 
collection included  175 isolates of C. albicans; 43 isolates of 
C. tropicalis; 12 isolates of C. krusei; 17 isolates of C. 
parapsilosis ; 5 isolates of C. glabrata ; 8 isolates of C. 
guilliermondii. Isolates were identified using conventional 
methods, growth in CHROM Agar media and using Atlas of 
fungi. They were stored as water suspension until used. Prior 
to testing, each isolate was passaged at least twice on SDA 
with chloramphenicol to ensure purity and viability.   
Antifungal  agents: Voriconazole (Pfizer), fluconazole 
(Pfizer), itraconazole (Jansen), flucytosine (Sigma), 
amphotericin B (Hi media). Serial two fold dilutions were 
prepared exactly as outlined in NCCLS document M 27A (17). 
Final dilutions were prepared in RPMI 1640 medium (Sigma) 
buffered to pH 7.0 with 0.165M morpholine propane sulphonic 
acid (MOPS) buffer (Sigma). The dilutions were kept in 
Eppendorf’s tubes until used and stored at -4°C in Quick 
freezer.  
Natural products: Turmeric, cinnamon, clove, ginger, garlic, 
neem, tulsi were used for the present study. The natural 
products were dried, powdered and then alcoholic extracts 
were prepared. The discs of natural products were prepared by 
soaking the discs in alcoholic extracts for a period of 24 hours 
and then dried in air. Two fold dilutions were prepared from 
powdered form in RPMI 1640 medium for broth dilution 
method. 
Susceptibility testing: Reference antifungal Susceptibility 
testing of Candida species was performed by disc diffusion 
method as described by Barry et al (5) and BMD method as 
described in NCCLS documents (17). MIC’s were determined 
with RPMI 1640 agar. An inoculum suspension adjusted to the 
turbidity of a 0.5 McFarland standard (~106cells/ml), and 
incubation at 35°C for 48 hours. MIC interpretive criteria were 
those published by Rex et al and the NCCLS document M 27 A 
and were as follows: susceptible, MIC <8µg/ml; susceptible-
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dose dependent, MIC = 16 to 32µg/ml; resistant, MIC > 
64µg/ml. The interpretive criteria for disc test were those 
published by Barry et al.5 and the NCCLS document M 27 A 
(17): susceptible, zone diameter of > 19mm; susceptible-dose 
dependent, zone diameter of 15 – 18 mm; resistant, zone 
diameter of < 14mm. 
Quality control: QC was performed for BMD & disc diffusion 
method in accordance with NCCLS document M 27 A17 by 
using C. albicans 3809 as reference culture. 
Analysis of results: The diameters of the zone of inhibition for 
the test antifungals were measured in mm by disc diffusion 
method and their respective BMD MIC’s were also studied. 
The errors were identified as susceptibility by one method and 
resistivity by other method. 
Results and Discussion 
The species distribution of Candida isolates in present 
investigation is summarized in Table 1. These isolates were 
obtained during the course of Candida surveillance studies and 
represent a total of 260 clinical isolates. Most of the species of 
Candida isolated in present study have been previously 
reported to cause serious infections in humans19,20,21, 22.
 
Table 1: Species distribution of Candida isolates 
Species isolated No. of isolates % of isolates 
Candida albicans 175 67.32 
Candida tropicalis 43 16.54 
Candida krusei 12 4.61 
Candida parapsilosis 17 6.54 
Candida glabrata 5 1.92 
Candida guilliermondii 8 3.07 
Total 260 100 
 
       Several species such as C. krusei, C. guilliermondii, 
and C. parapsilosis have been reported to express resistance 
to antifungal agents. Thus, it is evident that these non albicans 
species of Candida may be considered as opportunistic 
pathogens and that these may be responsible in posing 
resistance problems for the currently used antifungal agents. 
From the table it is clear that the most frequently encountered 
Candida species is C. albicans followed by C. tropicalis, C. 
parapsilosis, C. krusei etc.  The antifungal susceptibilities of 
the isolated Candida species are summarized in Table 2.
 
Table 2: In vitro susceptibility of Candida species against various antifungals 
Antifungals AMP B  5 FC FLU VORI ITRA 
Susceptibility S I R S I R S I R S I R S I R 
Disc diffusion  203 41 16 240 09 11 135 65 60 198 32 30 146 88 26 
Broth dilution 196 53 11 168 75 17 112 98 50 206 28 26 185 69 06 
AMP B –Amphotericin B, 5FC- 5 Fluocytosine, FLU-Fluconazole, VORI-Voriconazole, ITRA-Itraconazole. 
S-Sensitive; I-Intermediate; R-Resistant.   
 
Table 3: In vitro susceptibility of Candida species against alcoholic extract of various natural herbs and spices measured as zone of inhibition in cms  
                 
The clinical isolates resistant to antifungal were selected 
and subjected to the in vitro sensitivity against the natural 
products .The sensitivity of the strains was measured as zone 
of inhibition in cms. The sensitivity of the clinical isolates to 
natural extracts is expressed in table 3.The mean value of the 
number of isolates for each strain was studied. From the table 
it is clear that the resistant strains of clinically isolated Candida 
spp. are sensitive to spices and herbs used as a supplement in 
diet.  The most effective amongst all the spices and herbs is 
garlic (Allium sativum), followed by onion(Allium cepa), neem 
(Azadirachta indica), ginger (Zingiber officinale) and Aloe vera.  
Amongst all the Candida strains tested the neem extract was 
found to be effective against C. albicans and C. krusei followed 
by C. tropicalis, C. parapsilosis and C. glabrata. Tulsi (Ocimum 
sanctum) extract was found to be least effective. The 
antifungal activities of some spices and herbs have been 
reported by Anupam et al. 2005. The results of the present 
investigation are according to those obtained by Anupam et al. 
It is clearly illustrated from the table that the common spices 
used in our daily life and the extracts of natural herbs effects 
S. 
No 
Clinical fungal isolate No. of 
isolate   
neem tulsi ginger Garlic onion Aloe vera 
1 Candida 
albicans 
16 1.4 0.4 1.0 1.6 1.8 0.6 
2 Candida 
tropicalis 
12 1.2 - - 1.8 1.3 0.5 
3 Candida 
 krusei 
05 1.4 0.4 1.2 1.5 1.2 - 
4 Candida parapsilosis 04 1.2 - 1.0 1.6 1.3 0.5 
5 Candida  
glabrata 
07 1.2 - 1.0 1.6 1.4 0.4 
6 Candida guilliermondii 03 1.0 - 1.2 1.4 - 0.6 
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the fungal growth adversely and therefore might be considered 
to control fungal diseases. The bioactive compounds in these 
plant extracts must be analyzed, purified and then can be used 
as drug for controlling fungal pathogens without the 
development of drug resistance in pathogens and also without 
any side effects. 
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